ExploreWatchlistsPricing
  1. JP-listed companies
  2. HEALIOS K.K.
  3. Financials
  4. Net income

HEALIOS K.K. (4593)

Market cap
¥49.5B
P/E ratio
Helios develops stem cell treatments for hard-to-treat diseases using both somatic stem cells and iPS cells to create regenerative medicines.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income (Million JPY)YoY (%)
Dec 31, 2025-2,217-47.65%
Dec 31, 2024-4,235+10.78%
Dec 31, 2023-3,823-26.04%
Dec 31, 2022-5,169+5.27%
Dec 31, 2021-4,910-10.92%
Dec 31, 2020-5,512+24.99%
Dec 31, 2019-4,410-13.48%
Dec 31, 2018-5,097+186.89%
Dec 31, 2017-1,777-48.26%
Dec 31, 2016-3,434+258.37%
Dec 31, 2015-958+100.75%
Dec 31, 2014-477-660.55%
Dec 31, 201385-314.71%
Dec 31, 2012-40-17340.87%
Dec 31, 20110

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat